Jubilant Pharmova Limited — Others, 05-08-2025: Shareholders meeting

Jubilant Pharmova announced its 47th Annual General Meeting via video conferencing, alongside its annual report. The company showcased robust FY25 financial performance, with revenue growing 8% to ₹7,234.5 crore and EBITDA up 24% to ₹1,230 crore. Normalised profit after tax more than doubled to ₹415.2 crore, and net debt-to-EBITDA significantly improved to 1.1x from 2.5x. This strong foundation supports its Vision 2030, aiming for doubled revenue, 23-25% EBITDA margins, and zero net debt. Shareholders will consider a ₹5 per share dividend and director re-appointments. The board appointed M/s. Sanjay Grover & Associates as Secretarial Auditors for five years.